Unique ID issued by UMIN | UMIN000003641 |
---|---|
Receipt number | R000004391 |
Scientific Title | Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma. |
Date of disclosure of the study information | 2010/05/19 |
Last modified on | 2014/05/23 10:42:35 |
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.
Japan |
CD20-positive B-cell lymphoma
Hematology and clinical oncology |
Malignancy
NO
To investigate safety and efficacy on combination therapy of auto-gamma/delta T cell therapy and rituximab for CD20-positive B-cell lymphoma
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Safety : Adverse events
Overall survival
Event free survival
Response of measurable lesion
Immunological responses
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
Patients receive auto-gamma/delta T cell therapy (day1) and rituximab (day8) every 2 weeks.
This treatment repeats 6 courses.
20 | years-old | <= |
Not applicable |
Male and Female
B-cell lymphoma patients who meet the following:
- CD20-positive;
- Performance status is 0-1;
- No serious abnormality in heart, lung, bone marrow, liver, and renal functions.
Patients who have:
- Active enteritis;
- Active autoimmune diseases;
- Active infections;
- Other cancers;
- Other serious complications;
- Continuous systemic administration of steroids.
15
1st name | |
Middle name | |
Last name | Kenshi Suzuki |
Japanese Red Cross Medical Center
Hematological Department
4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
1st name | |
Middle name | |
Last name |
Japanese Red Cross Medical Center
Hematological Department
4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
Japanese Red Cross Medical Center
Medinet Co.,Ltd.
Profit organization
Japan
Seta Clinic Group
NO
日本赤十字社医療センター(東京都)、瀬田クリニック東京(東京都)
2010 | Year | 05 | Month | 19 | Day |
Published
Completed
2010 | Year | 02 | Month | 03 | Day |
2010 | Year | 05 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
8th Japan Research Association for immunotherapeutics(2011.2.26)
2010 | Year | 05 | Month | 19 | Day |
2014 | Year | 05 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004391
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |